title: [Standard hepatitis B therapy].
abstract: Standard treatment of chronic hepatitis B virus infection includes the use of interferon-a and antiviral nucleoside analogues, alternatively. In general, in patients with hepatic inflammatory activity, low viral titers and HBe positive wild-type infection interferon leads to a long-term seroconversion rate of about 30-50%. However in patients with advanced liver disease, in interferon non-responders and HBe minus mutants HBV carriers nucleoside analogues like lamivudine represents a new and clinically proven therapeutical option. However, the longterm outcome and the problem of the emergence of HBV polymerase gene mutants has not been completely understood.
authors.affiliation: Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik Essen.
authors.forename: G
authors.initials: G
authors.lastname: Gerken
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine